Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?
Bladder Cancer · 01.09.2023 · 9 (3) · 201-210
DOI: 10.3233/blc-230039 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bladder Cancer, online erschienen am 11.08.2023. Verfasst von Vivek Kumar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Boston, MA, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The introduction of T-cell targeted immunomodulators blocking the PD-1 and PD-L1 axis is unquestionably one of the most notable advancements in the treatment of advanced or metastatic solid malignancies, including bladder cancer. Immune checkpoint antibodies are now widely utilized as monotherapies or in combination with other systemic therapies in the first or subsequent lines of treatment in approximately 50 cancer types. Deep and durable responses and long tails of survival curves are hallmarks of patients treated with immune checkpoint inhibitors. However, treatment can have negative impacts, including serious treatment-related side effects as well as a high financial burden to individual patients and the healthcare system. There is increasing data that the benefit of immune checkpoint treatment may persist after treatment is discontinued for reasons other than progressive disease, particularly in patients who have achieved a durable complete response. However, the optimal treatment duration and activity after treatment reinitiation remains undefined and will likely be influenced by disease biology (histology and genomics), treatment (monotherapy or combination therapy), and disease context (depth and duration of response). Well-designed prospective clinical trials and the development and validation of biomarkers that predict outcomes after treatment cessation are needed to move the field forward.
Autor:innen und Institutionen
- Brigham and Women's Hospital, Boston, MA, USA.
- Dana-Farber Cancer Institute, Boston, MA, USA.
Zitieren
APA
Kumar, V., & Wei, X. X. (2023). Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?. Bladder Cancer, 9(3), 201-210. https://doi.org/10.3233/blc-230039
Vancouver
Kumar V, Wei XX. Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?. Bladder Cancer. 2023;9(3):201-210. doi:10.3233/blc-230039
BibTeX
@article{Kumar2023,
author = {Kumar, Vivek and Wei, Xiao X},
title = {Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?},
journal = {Bladder Cancer},
year = {2023},
volume = {9},
number = {3},
pages = {201--210},
doi = {10.3233/blc-230039}
}
EUVIMED